NCT01681212 Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma Status COMPLETED Phase PHASE2
NCT01676649 Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT01673854 Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma Status COMPLETED Phase PHASE2
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT01643278 Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic Status COMPLETED Phase PHASE1
NCT01621490 PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma Status COMPLETED Phase PHASE1
NCT01611558 Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer Status COMPLETED Phase PHASE2
NCT01604889 A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma Status TERMINATED Phase PHASE1/PHASE2
NCT01592370 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT01590082 Doxycycline, Temozolomide and Ipilimumab in Melanoma Status TERMINATED Phase PHASE1/PHASE2
NCT01585987 An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy Status COMPLETED Phase PHASE2
NCT01585194 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Status COMPLETED Phase PHASE2
NCT01565837 Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma Status UNKNOWN Phase PHASE2
NCT01557114 Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma Status TERMINATED Phase PHASE1
NCT01524991 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Status COMPLETED Phase PHASE2
NCT01515189 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Status COMPLETED Phase PHASE3
NCT01502592 Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer Status COMPLETED Phase PHASE1
NCT01498978 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Status COMPLETED Phase PHASE2
NCT01497808 RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA Status COMPLETED Phase PHASE1/PHASE2